These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 34063871)

  • 21. Influenza virus-like particles composed of conserved influenza proteins and GPI-anchored CCL28/GM-CSF fusion proteins enhance protective immunity against homologous and heterologous viruses.
    Liu J; Ren Z; Wang H; Zhao Y; Wilker PR; Yu Z; Sun W; Wang T; Feng N; Li Y; Wang H; Ji X; Li N; Yang S; He H; Qin C; Gao Y; Xia X
    Int Immunopharmacol; 2018 Oct; 63():119-128. PubMed ID: 30081250
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IgG and IgM responses to human papillomavirus L1 virus-like particle as a function of dosing schedule and vaccine formulation.
    Park MH; You JW; Kim HJ; Kim HJ
    J Microbiol; 2019 Sep; 57(9):821-827. PubMed ID: 31452045
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines.
    Da Silva DM; Pastrana DV; Schiller JT; Kast WM
    Virology; 2001 Nov; 290(2):350-60. PubMed ID: 11883199
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel C-terminal modification method enhanced the yield of human papillomavirus L1 or chimeric L1-L2 virus-like particles in the baculovirus system.
    Ma M; Xia B; Wang Z; Hao Y; Zhang T; Xu X
    Front Bioeng Biotechnol; 2022; 10():1073892. PubMed ID: 36686228
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses.
    Pouyanfard S; Spagnoli G; Bulli L; Balz K; Yang F; Odenwald C; Seitz H; Mariz FC; Bolchi A; Ottonello S; Müller M
    J Virol; 2018 Feb; 92(4):. PubMed ID: 29212932
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Immunogenicity of Capsid-Like Particle Vaccines in Combination with Different Adjuvants Using Different Routes of Administration.
    Janitzek CM; Carlsen PHR; Thrane S; Khanna VM; Jakob V; Barnier-Quer C; Collin N; Theander TG; Salanti A; Nielsen MA; Sander AF
    Vaccines (Basel); 2021 Feb; 9(2):. PubMed ID: 33562114
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of meningococcal polysaccharide conjugate vaccine that can elicit long-lasting and strong cellular immune response with hepatitis B core antigen virus-like particles as a novel carrier protein.
    Xu L; Li Z; Su Z; Yang Y; Ma G; Yu R; Zhang S
    Vaccine; 2019 Feb; 37(7):956-964. PubMed ID: 30655174
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improving the malaria transmission-blocking activity of a Plasmodium falciparum 48/45 based vaccine antigen by SpyTag/SpyCatcher mediated virus-like display.
    Singh SK; Thrane S; Janitzek CM; Nielsen MA; Theander TG; Theisen M; Salanti A; Sander AF
    Vaccine; 2017 Jun; 35(30):3726-3732. PubMed ID: 28578824
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chimeric virus-like particles of the human papillomavirus type 16 (HPV 16) as a prophylactic and therapeutic vaccine.
    Jochmus I; Schäfer K; Faath S; Müller M; Gissmann L
    Arch Med Res; 1999; 30(4):269-74. PubMed ID: 10573627
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical Efficacy of a Capsid Virus-like Particle-Based Vaccine Targeting IL-1β for Treatment of Allergic Contact Dermatitis.
    Goksøyr L; Funch AB; Okholm AK; Theander TG; de Jongh WA; Bonefeld CM; Sander AF
    Vaccines (Basel); 2022 May; 10(5):. PubMed ID: 35632584
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccine synergy with virus-like particle and immune complex platforms for delivery of human papillomavirus L2 antigen.
    Diamos AG; Larios D; Brown L; Kilbourne J; Kim HS; Saxena D; Palmer KE; Mason HS
    Vaccine; 2019 Jan; 37(1):137-144. PubMed ID: 30459071
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix™ in mice.
    Han JE; Wui SR; Park SA; Lee NG; Kim KS; Cho YJ; Kim HJ; Kim HJ
    Vaccine; 2012 Jun; 30(28):4127-34. PubMed ID: 22561312
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced mucosal and systemic immune responses following intravaginal immunization with human papillomavirus 16 L1 virus-like particle vaccine in thermosensitive mucoadhesive delivery systems.
    Park JS; Oh YK; Kang MJ; Kim CK
    J Med Virol; 2003 Aug; 70(4):633-41. PubMed ID: 12794729
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Novel Human Papillomavirus 16 L1 Pentamer-Loaded Hybrid Particles Vaccine System: Influence of Size on Immune Responses.
    Jia C; Yang T; Liu Y; Zhu A; Yin F; Wang Y; Xu L; Wang Y; Yan M; Cai Q; Liang X; Ju R; Chen J; Wang L
    ACS Appl Mater Interfaces; 2018 Oct; 10(42):35745-35759. PubMed ID: 30360122
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
    J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Modular Antigen Presenting Peptide/Oligonucleotide Nanostructure Platform for Inducing Potent Immune Response.
    Tohumeken S; Gunduz N; Demircan MB; Gunay G; Topal AE; Khalily MA; Tekinay T; Dana A; Guler MO; Tekinay AB
    Adv Biosyst; 2017 May; 1(5):e1700015. PubMed ID: 32646154
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Covalent protein display on Hepatitis B core-like particles in plants through the in vivo use of the SpyTag/SpyCatcher system.
    Peyret H; Ponndorf D; Meshcheriakova Y; Richardson J; Lomonossoff GP
    Sci Rep; 2020 Oct; 10(1):17095. PubMed ID: 33051543
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials.
    Van Damme P; Leroux-Roels G; Simon P; Foidart JM; Donders G; Hoppenbrouwers K; Levin M; Tibaldi F; Poncelet S; Moris P; Dessy F; Giannini SL; Descamps D; Dubin G
    Vaccine; 2014 Jun; 32(29):3694-705. PubMed ID: 24674663
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of a Modular Vaccine Platform for Multimeric Antigen Display Using an Orthobunyavirus Model.
    Aebischer A; Wernike K; König P; Franzke K; Wichgers Schreur PJ; Kortekaas J; Vitikainen M; Wiebe M; Saloheimo M; Tchelet R; Audonnet JC; Beer M
    Vaccines (Basel); 2021 Jun; 9(6):. PubMed ID: 34203630
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Encapsidating artificial human papillomavirus-16 mE7 protein in human papillomavirus-6b L1/L2 virus like particles.
    Xu YF; Wang QY; Zhang HT; Han YH; Song GX; Xu XM
    Chin Med J (Engl); 2007 Mar; 120(6):503-8. PubMed ID: 17439745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.